Biomarker study for afatinib plus bevacizimab
Not Applicable
- Conditions
- on-small cell lung cancer with EGFR mutations
- Registration Number
- JPRN-UMIN000032489
- Lead Sponsor
- Okayama University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
nothing in particular
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The frequency of development ofEGFR T790M between afatainib arm and afatinib/Bev arm
- Secondary Outcome Measures
Name Time Method The effect of afatiib or afatinib/Bev based on EGFR T790M status The effect of subsequent therapies including osimertinib